Drugs / FIRTECAN PEGOL
FIRTECAN PEGOL
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01251926 | Nov 2010 → Apr 2014 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00520637 | May 2007 → ? | cancer, lymphoma | Enzon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00520390 | May 2007 → ? | cancer, lymphoma | Enzon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01295697 | Feb 2010 → Aug 2012 | cancer | Enzon Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01036113 | Nov 2009 → Feb 2012 | breast cancer | Enzon Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00931840 | Jun 2009 → Oct 2011 | colorectal cancer | Enzon Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIRTECAN PEGOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594234 ↗ |
| Known as | EZN-2208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01251926 ↗ |
| Known as | PEG-SN38 | “A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week...” NCT00520390 ↗2“A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)” NCT00931840 ↗ “Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks” NCT00520637 ↗ |
| Known as | PEGylated SN-38 | “EZN-2208 (PEGylated SN-38)” NCT01251926 ↗ |
| Route | Intravenous | “Intravenous EZN-2208” NCT00520390 ↗ |